A phase III multi-center, double-blind, placebo-controlled, parallel group 24-week study to assess the efficacy and safety of two dose regimens of liquid certolizumab pegol [Cimzia] as additional medication to methotrexate in the treatment of signs and symptoms of rheumatoid arthritis and in prevention of joint damage in patients with active rheumatoid arthritis who have an incomplete response to methotrexate.

Trial Profile

A phase III multi-center, double-blind, placebo-controlled, parallel group 24-week study to assess the efficacy and safety of two dose regimens of liquid certolizumab pegol [Cimzia] as additional medication to methotrexate in the treatment of signs and symptoms of rheumatoid arthritis and in prevention of joint damage in patients with active rheumatoid arthritis who have an incomplete response to methotrexate.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2017

At a glance

  • Drugs Certolizumab pegol (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms RAPID-2
  • Sponsors UCB
  • Most Recent Events

    • 10 May 2011 Results from a post hoc analysis of this trial (RAPID-2) have been published in the Annals of Rheumatic Diseases according to a UCB media release; results were also reported in the media release.
    • 17 Mar 2011 Secondary endpoint results published in the Annals of the Rheumatic Diseases.
    • 23 Feb 2011 Actual end date changed from 1 Sep 2006 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top